Bioequivalence Test of "Dong-a Bepotastine Besilate Tab" and "Twolion Tab"

NCT ID: NCT03932435

Last Updated: 2020-02-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-04-23
• Study Completion Date: 2019-05-28

Brief Summary

An Open-Label, Randomized, 2-sequence, 2-period, Fasted Condition, Single-dose, Per Oral, Cross-over Study to Evaluate the Bioequivalence of "Dong-a Bepotastine Besilate Tab" (Bepotastine Besilate 10mg) and "Twolion Tab" (Bepotastine Besilate 10mg) in Healthy Volunteers

Detailed Description

1. Study design: An open-Label, randomized, 2-sequence, 2-period, fasted condition, single-dose, per oral, cross-over study

2. Administration method:

The subject should maintain a minimum of 10 hours of empty stomach before administration, and give an oral dose of 1 tablets (Bepotastine Besilate 10 mg) with 150 mL of water at around 8 a.m. on the day of the test at room temperature. The test subject should not chew the drug or break it, but should swallow in whole with water. The difference in administration time between the test subjects is about one minute apart, considering the collection time.

3. Wash out period: 7 days

4. Blood collection time: Before the administration, 0.25, 0.5, 0.75, 1, 1.33, 1.67, 2, 3, 4, 6, 8, 12 hr after the administration (total 13 times)

5. Analysis: Measurement of the concentration of an unchangeable substance of Bepotastine in plasma

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

TWLO_C → TWLO

TWLO\_C: "Dong-a Bepotastine Besilate Tab" (Bepotastine Besilate 10mg), TWLO: "Twolion Tab" (Bepotastine Besilate 10mg)

Group Type: EXPERIMENTAL

Fisrt period TWLO_C

Intervention Type: DRUG

First Period: Single oral administration of 1 tablet of "Dong-a Bepotastine Besilate Tab"(Bepotastine Besilate 10mg)

Washout period

Intervention Type: OTHER

7 days

Second period TWLO

Intervention Type: DRUG

Second Period: Single oral administration of 1 tablet of "Twolion Tab"(Bepotastine Besilate 10mg)

TWLO → TWLO_C

TWLO\_C: "Dong-a Bepotastine Besilate Tab" (Bepotastine Besilate 10mg), TWLO: "Twolion Tab" (Bepotastine Besilate 10mg)

Group Type: EXPERIMENTAL

Fisrt period TWLO

Intervention Type: DRUG

First Period: Single oral administration of 1 tablet of "Twolion Tab"(Bepotastine Besilate 10mg)

Washout period

Intervention Type: OTHER

7 days

Second period TWLO_C

Intervention Type: DRUG

Second Period: Single oral administration of 1 tablet of "Dong-a Bepotastine Besilate Tab"(Bepotastine Besilate 10mg)

Interventions

Fisrt period TWLO_C

First Period: Single oral administration of 1 tablet of "Dong-a Bepotastine Besilate Tab"(Bepotastine Besilate 10mg)

Intervention Type: DRUG

Fisrt period TWLO

First Period: Single oral administration of 1 tablet of "Twolion Tab"(Bepotastine Besilate 10mg)

Intervention Type: DRUG

Washout period

7 days

Intervention Type: OTHER

Second period TWLO_C

Second Period: Single oral administration of 1 tablet of "Dong-a Bepotastine Besilate Tab"(Bepotastine Besilate 10mg)

Intervention Type: DRUG

Second period TWLO

Second Period: Single oral administration of 1 tablet of "Twolion Tab"(Bepotastine Besilate 10mg)

Intervention Type: DRUG

Other Intervention Names

"Dong-a Bepotastine Besilate Tab"; "Twolion Tab"; "Dong-a Bepotastine Besilate Tab"; "Twolion Tab"

Eligibility Criteria

Inclusion Criteria

1. A person who aged 19 or older at the time of screening

2. No congenital or chronic diseases or pathological symptoms on screening

3. A person who is judged to be suitable for the study by the investigator based on the clinical laboratory examination

4. BMI of 18 to 30 (BMI calculation: kg/m2)

5. No history of gastrointestinal resection that may affect the absorption of drugs

6. No medical history of mental illness within five years prior to screening

7. A person who has fully understood the contents of the consent form for the study and signed the consent form voluntarily and recorded the date of signature

8. A person who is willing and able to follow all scheduled hospitalization and outpatient visits, medications, clinical laboratory examination and the terms of compliance

9. Female patients who were confirmed to be not pregnant at medical examination

Exclusion Criteria

1. A person who has taken a drug that significantly induces (e.g., barbital) or inhibits the drug metabolic enzyme within 30 days prior to screening

2. A person who uses drugs that can affect the study within 10 days before screening

3. A person who is considered unsuitable to participate in the study by the investigator

4. A person who has participated in other clinical trials within three months prior to the first administration of the IP

5. A person who has had whole blood transfusion within 2 months or the apheresis within 2 weeks before screening

6. A person who is hypersensitive to venipuncture

7. A person with a history of regular alcohol intake within six months prior to screening:

• Women: More than 14 cups/week
• Men: More than 21 glasses/week (1 shot: 50 ml of soju, 30 ml of spirits, 250 ml of beer)

8. Hypersensitive to any of the IP components

9. Blood AST (GOT) or ALT (GPT) levels exceed the upper reference range limit by 2 times or γ-GTP levels exceed the upper reference range limit by 1.5 times

10. Lactating women

11. A person who does not agree to exclude the possibility of pregnancy using the contraception from the date of the first administration of the IP until the 7th day after the last administration.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Dong-A ST Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

H Plus Yangji Hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

TWLO_BE_01

Identifier Type: -

Identifier Source: org_study_id